Condition: Melanoma (Skin) · Melanoma, Stage II, Stage I · Melanoma Stage · Sponsor: Erasmus Medical Center
A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.
This description comes directly from the study's public registry record.
Marjolein Lugtenberg, PhD · +31614448940 · m.lugtenberg@erasmusmc.nl
June Kievits, MD · j.kievits@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Albert Schweitzer hospital | Dordrecht, South Holland, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, South Holland, Netherlands | Recruiting |
| Franciscus Gasthuis & Vlietland hospital | Rotterdam, South Holland, Netherlands | Not Yet Recruiting |
| Maasstad hospital | Rotterdam, South Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06643286